Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BeiGene, Ltd. - American Depositary Shares (OQ:BGNE)

Business Focus: N/A

Mar 14, 2024 04:28 pm ET
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in the second half of 2024.
Mar 13, 2024 08:00 am ET
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymphocytic leukemia (CLL) to patients in Armenia and Nepal, as part of a three-year
Mar 07, 2024 05:19 pm ET
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication is approved under accelerated approval based on response rate and durability of response, marking BRUKINSA’s fifth indication in B-cell malignancies in the
Mar 06, 2024 06:00 am ET
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting April 5-10 in San Diego. BeiGene has nine abstracts scheduled for poster presentations at AACR.
Feb 29, 2024 10:00 am ET
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials. The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival. These data will be presented during the 28th Annual International Congress
Feb 28, 2024 08:05 am ET
BeiGene to Present at Upcoming Investor Conferences
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences:
Feb 27, 2024 06:00 am ET
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for TEVIMBRA® (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The FDA’s action date on the BLA is expected in December 2024.
Feb 26, 2024 06:00 am ET
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today reinforced its continued global expansion, rapid global and U.S. revenue growth, and innovative R&D strategy with the presentation of results from the fourth quarter and full year 2023 and business highlights.
Feb 26, 2024 05:00 am ET
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications:
Feb 07, 2024 05:47 am ET
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in Canada
Jan 31, 2024 05:47 am ET
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)
BRUKINSA is now listed on the RAMQ and ODB formularies.Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings.Approximately 2,000 Canadians are diagnosed every year with CLL, the most common form of leukemia in adults.TORONTO, Jan. 31, 2024 /CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and Quebec have publicly listed BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), f
Jan 23, 2024 06:00 am ET
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board.
Dec 22, 2023 06:00 am ET
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).
Dec 21, 2023 06:01 am ET
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT.
Nov 29, 2023 04:01 pm ET
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.
Nov 28, 2023 06:00 am ET
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.
Nov 21, 2023 06:00 am ET
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Nov 17, 2023 06:00 am ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has granted marketing authorization for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. This marks the fourth indication in the European Union (EU) for BRUKINSA, which is now approved to treat more patient populations in the EU than any other Bruton’s tyrosine kinase (BTK) inhibito
Nov 09, 2023 04:01 pm ET
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the third quarter of 2023 and business highlights.
Nov 08, 2023 06:00 am ET
BeiGene to Present at the Jefferies London Healthcare Conference
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 with a fireside chat at 2:00 pm GMT.
Oct 30, 2023 09:31 am ET
Thinking about trading options or stock in NVIDIA, Apple, JinkoSolar, Beigene, or Netflix?
NEW YORK, Oct. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, AAPL, JKS, BGNE, and NFLX.
Oct 20, 2023 06:00 am ET
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a final draft guidance (FDG) recommending BRUKINSA® (zanubrutinib) for the treatment of eligible adult patients with:
Oct 17, 2023 04:01 pm ET
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junctio
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). No new safety signals were identified. Study results will be featured as a late-breaking oral presentation on October 21 at 5:25 p.m. CEST at the European Society for Medical Oncology (ESMO
Oct 17, 2023 04:01 pm ET
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-S
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by Blinded Independent Central Review (BICR), demonstrating statistically significant and clinically meaningful improvements in patients with resectable Stage II or IIIA NSCLC treated with tislelizumab in combination with chemotherapy before surgery and as a single agent after surgery versus neoadjuvant chemother
Oct 16, 2023 06:00 am ET
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023.
Oct 13, 2023 11:51 am ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase inhibitor (BTKi), in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy.
Sep 19, 2023 06:15 am ET
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved TEVIMBRA® (tislelizumab) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. Additionally, the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metast
Sep 19, 2023 06:00 am ET
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
Sep 11, 2023 09:31 am ET
Thinking about trading options or stock in Hostess Brands Inc, Beigene Ltd, Xpeng Inc - ADR, Enbridge Inc, or Docusign Inc?
NEW YORK, Sept. 11, 2023 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for TWNK, BGNE, XPEV, ENB, and DOCU.
Aug 31, 2023 07:00 am ET
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11th, 2023 with a fireside chat at 9:20 am ET.
Aug 02, 2023 06:00 am ET
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.
Jul 21, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. (NASDAQ: VSAT) and BeiGene Ltd. (NASDAQ: BGNE). Our investigations concern whether these companies have...
Jul 21, 2023 07:50 am ET
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy.
Jul 17, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jul 16, 2023 08:39 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Castle Biosciences, Inc. (NASDAQ: CSTL), Coinbase Global, Inc. (NASDAQ: COIN), Arrival SA (NASDAQ: ARVL), and BeiGene Ltd....
Jul 12, 2023 07:00 am ET
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy. BRUKINSA was previously granted Fast Track and Orphan designation for this indication. The FDA has assigned a target action date in the firs
Jul 11, 2023 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jul 10, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA). Our investigations concern whether these companies have violated the...
Jul 10, 2023 07:00 am ET
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.
Jul 07, 2023 07:00 am ET
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Company's leadership team, will provide an update on BeiGene’s deep and broad global innovation pipeline and platforms, and share insights on the Company's vision, differentiated capabilities, and value creation drivers.
Jul 06, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jul 05, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp. (NASDAQ: FOX, FOXA) and BeiGene Limited (NASDAQ: BGNE). Our investigations concern whether these companies have...
Jul 03, 2023 01:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jul 01, 2023 10:40 am ET
ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially...
Jun 30, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EPAM Systems, Inc. (NYSE: EPAM), Castle Biosciences, Inc. (NASDAQ: CSTL), BeiGene, Ltd. (NASDAQ: BGNE), and Fox Corp....
Jun 29, 2023 04:10 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 26, 2023 09:00 pm ET
BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal securities laws and/or engaged in other unlawful business practices.
Jun 26, 2023 12:45 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 25, 2023 04:00 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially misleading...
Jun 20, 2023 02:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 18, 2023 08:15 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 17, 2023 04:21 pm ET
BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially...
Jun 17, 2023 08:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 16, 2023 07:36 pm ET
BeiGene, Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises BeiGene, Ltd. (“BeiGene” or “the Company”) (NASDAQ: BGNE) investors that the law firm has initiated an investigation on behalf of investors that lost money on their BeiGene stock. BeiGene investors are encouraged to...
Jun 16, 2023 05:04 pm ET
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)
The law firm of Kirby McInerney LLP is investigating potential claims against BeiGene Ltd. (“BeiGene” or the “Company”) (NASDAQ:
Jun 16, 2023 09:00 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. (“BeiGene” or “the Company”) (NASDAQ:
Jun 16, 2023 07:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or "the Company") (NASDAQ:BGNE) for violations of the securities laws.
Jun 15, 2023 08:24 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd. (“BeiGene” or “the Company”) (NASDAQ:
Jun 15, 2023 04:53 pm ET
BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially misleading business information to the investing public.
Jun 15, 2023 09:31 am ET
Thinking about trading options or stock in Plug Power, Microvision, Beigene, Zai Lab, or NVIDIA?
NEW YORK, June 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, MVIS, BGNE, ZLAB, and NVDA.
Jun 15, 2023 08:37 am ET
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023. BeiGene’s work is original, and we will vigorously defend against all allegations of patent infringement.
Jun 15, 2023 03:00 am ET
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will present data on its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA® (zanubrutinib) at the 17th International Conference on Malignant Lymphoma (ICML), which is taking place from June 13-17 in Lugano, Switzerland.
Jun 09, 2023 03:01 am ET
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data from its broad blood cancer portfolio of approved therapies and promising early-stage pipeline products at the 2023 European Hematology Association (EHA) Hybrid Congress. BeiGene has ten accepted abstracts at EHA, which is taking place from June 8-11 in Frankfurt, Germany.
May 30, 2023 07:00 am ET
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
May 30, 2023 07:00 am ET
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults
Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings
May 25, 2023 05:05 pm ET
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data showcasing the range of BeiGene’s research expertise and the productivity of one of the industry’s largest research and development teams at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor.
May 24, 2023 07:00 am ET
BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences:
May 17, 2023 07:00 am ET
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and M
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years. This collaboration advances each organization’s focus on patient access by combining Max’s exp
May 06, 2023 08:00 am ET
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib), the company’s Bruton’s tyrosine kinase inhibitor (BTKi), including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and Waldenström's macroglobulinemia (WM), and two Supplemental Applications for conversions from conditional approval to regular approval.
May 04, 2023 07:00 am ET
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones.
Apr 26, 2023 10:27 am ET
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago, June 2-6, 2023.
Apr 25, 2023 07:00 am ET
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the Company’s newly released “Change Is the Cure: 2022 Environmental, Social and Governance Report.” The report highlights BeiGene’s ESG strategy, the progress the Company has made against past goals, and how it intends to achieve its bold new targets.
Apr 20, 2023 07:00 am ET
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy demonstrating superior overall survival (OS) compared with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 status. No new safety signals were identified for tislelizumab.
Apr 17, 2023 02:32 pm ET
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberrations. The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.
Apr 17, 2023 02:32 pm ET
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in...
Apr 17, 2023 02:30 pm ET
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.
Apr 17, 2023 02:30 pm ET
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational,...
Apr 13, 2023 07:00 am ET
BeiGene Expands Presence in Latin America With Opening of Brazil Office
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the first major step in the company’s expansion in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil.
Mar 30, 2023 07:00 am ET
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.
Mar 21, 2023 07:00 am ET
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities that complement the company’s existing capabilities around the world.
Feb 27, 2023 07:00 am ET
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.
Feb 24, 2023 07:00 am ET
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the China National Medical Products Administration (NMPA) granted approval for the company’s PD-1 inhibitor, tislelizumab, in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with high PD-L1 expression.
Feb 24, 2023 07:00 am ET
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen’s 43rd Annual Healthcare Conference on Monday, March 6th, 2023 with a fireside chat at 11:10 am ET.
Feb 06, 2023 05:37 am ET
Feb 03, 2023 07:00 am ET
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being. The data summarized in the report is based on a BeiGene-sponsored study by Cancer Support Community (CSC), a global nonprofit organization that provides free emotional support, navigation, and resources to cancer patients and their loved ones. The report and the newly launched CancerandMentalHealth.com website are part of the company’s comprehensive Talk About It: Cancer and Mental
Feb 01, 2023 07:00 am ET
BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:
Jan 19, 2023 05:03 pm ET
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Jan 19, 2023 07:00 am ET
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
Jan 18, 2023 08:27 am ET
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS® (carfilzomib), a proteosome inhibitor licensed-in from Amgen, is included for the first time and XGEVA® (denosumab), a RANKL inhibitor and another Amgen asset, successfully renewed this year. The updated NRDL will officially take effect on March 1, 2023.
Jan 17, 2023 05:00 pm ET
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium, notably, an oral presentation for interim results of the global pivotal phase 3 trial RATIONALE 305 of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction (G/GEJ) cancer. At the interim analysis, RATIONALE 305 trial met one of the primary endpoints of overall survival (OS) in patients with G/GEJ whose tumors express PD-L1.
Jan 04, 2023 07:07 am ET
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT.
Dec 30, 2022 09:00 am ET
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma (HCC).
Dec 13, 2022 10:00 am ET
 BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). These data will be presented (Abstract #LBA-6) during the late-breaking session at the 64th American Society of Hematology (A
Dec 09, 2022 07:00 am ET
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. In collaboration with Cancer Support Community (CSC), the company will preview new national survey findings1, including that 60 percent of individuals impacted by cancer who experienced emotional distress were not referred to a mental health professional by their cancer care team, and one in five
Dec 08, 2022 01:10 pm ET
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab
SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study  (NCT05431270) for the treatment of multiple advanced solid tumors.
Nov 22, 2022 08:30 am ET
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). The results will be presented at 10:1
Nov 17, 2022 07:00 am ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL.
Nov 15, 2022 07:00 am ET
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important intersection of mental health and cancer care to help improve health outcomes for cancer patients.
Nov 10, 2022 07:00 am ET
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
“We have carried out an expansive and global clinical development program for our innovative BTK inhibitor, BRUKINSA, which has led to approval for the treatment of WM, MZL, and MCL in Brazil. These approvals demonstrate our commitment to accelerate development and broaden access to innovative medicines around the globe,” said Alex Carvalho, Country General Manager, Brazil, at BeiGene. “I’m proud to bring this potentially best-in-class medicine to Brazil and look forward to working with our partner, Adium on commercialization activities.”
Nov 09, 2022 07:00 am ET
BeiGene Reports Third Quarter 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the third quarter of 2022, recent business highlights, and anticipated upcoming milestones.
Nov 04, 2022 07:00 am ET
BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:
Nov 03, 2022 09:00 am ET
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced clinical and real-world data accepted at the 64th American Society of Hematology (ASH) Annual Meeting, scheduled for December 10-14, 2022, in New Orleans. BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide.
Nov 02, 2022 07:00 am ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has granted marketing authorization of BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. The approval is applicable to all 27 member states of the European Union (EU), plus Iceland and Norway. BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients
Oct 26, 2022 07:00 am ET
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced significant progress in efforts to unlock global opportunities for BRUKINSA® (zanubrutinib) with recent regulatory approvals in six Latin American countries:
Oct 14, 2022 06:30 am ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Oct 12, 2022 07:00 am ET
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Tr
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) achieved superior Progression-Free Survival (PFS) versus IMBRUVICA® (ibrutinib) in a final analysis of the Phase 3 ALPINE trial, as assessed by an independent review committee (IRC) and investigator. BRUKINSA was generally well tolerated; safety findings at the final PFS analysis were consistent with pri
Sep 19, 2022 07:01 pm ET
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
Sep 19, 2022 07:00 am ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
Sep 10, 2022 02:30 am ET
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
Sep 07, 2022 07:27 pm ET
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET.
Aug 23, 2022 07:00 am ET
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (E
Aug 15, 2022 07:00 am ET
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with
Aug 09, 2022 06:00 am ET
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable hepatocellular carcinoma (HCC). The safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported. More than 600 patient
Aug 04, 2022 07:00 am ET
BeiGene Reports Second Quarter 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.
Jul 14, 2022 06:00 am ET
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for tislelizumab as a second-line (2L) treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The FDA has been unable to conduct required inspections in China due to COVID-19 related travel restrictions. As a result,
Jul 13, 2022 09:00 am ET
BeiGene Appoints Chan Lee as General Counsel
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022.
Jul 12, 2022 07:00 am ET
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with BeiGene
Jul 06, 2022 07:00 am ET
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics.
Jun 30, 2022 04:00 am ET
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) without prior systemic treatment for advanced disease. Study results presented today as a late-breaking oral presentation at the 2022 European Society for Medical Oncology (ESMO) Wor
Jun 21, 2022 07:00 am ET
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for the company’s anti-PD-1 inhibitor, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction adenoc
Jun 13, 2022 07:30 am ET
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has been approved by the Ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry of Public Health in Qatar for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BeiGene is working with NewBridge P
Jun 13, 2022 07:00 am ET
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to January 20, 2023 for the supplementary new drug application (sNDA) for BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Jun 10, 2022 07:00 am ET
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, presents data from its hematology portfolio at the European Hematology Association (EHA) 2022 Hybrid Congress being held June 9-12, 2022, in Vienna, Austria.
Jun 10, 2022 07:00 am ET
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody, tislelizumab, in co
Jun 08, 2022 08:00 am ET
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 8:40 a.m. PT.
May 26, 2022 05:00 pm ET
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, will present data from its broad solid tumor and hematology portfolios in eight presentations at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7, 2022. Highlights include new clinical data for its BTK-inhibitor zanubrutinib (BRUKINSA®):
May 17, 2022 01:00 am ET
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company’s operations in the region.
May 12, 2022 10:00 am ET
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at the European Hematology Association (EHA) 2022 Hybrid Congress being held June 9 – 12, 2022 in Vienna, Austria.
May 05, 2022 07:00 am ET
BeiGene Reports First Quarter 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones.
May 04, 2022 05:53 am ET
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). The NMPA granted conditional approval for adult patients in this indicatio
Apr 29, 2022 07:00 am ET
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewel
Apr 28, 2022 07:00 am ET
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the BTK inhibitor BRUKINSA (zanubrutinib) has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma (MCL), relapsed or refractory marginal zone lymphoma (MZL), and Waldenström’s macroglobulinemia (WM). BeiGene and Adium entered into an exclusive distribution agreement for Adium to commercialize BRUKINSA in
Apr 27, 2022 10:00 am ET
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced presentations from the Company’s global clinical development programs in hematologic malignancies and solid tumors at the 2022 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held on June 3-7, 2022.
Apr 27, 2022 06:00 am ET
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the Independent Data Monitoring Committee (IDMC) determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the study’s primary endpoint of overall survival (OS) in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). The safety
Apr 26, 2022 07:00 am ET
BeiGene Introduces Global Environmental, Social, and Governance Strategy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today introduced the Company’s global environmental, social, and governance (ESG) strategy.
Apr 25, 2022 04:09 pm ET
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
Apr 25, 2022 04:09 pm ET
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
BEIJING, April 25, 2022 /CNW/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
Apr 21, 2022 07:00 am ET
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for patients and their families across New Jersey, today announced a grant from BeiGene that will enable Crossroads4Hope to expand the reach of its psychosocial support programs to more vulnerable patients and communities.
Apr 19, 2022 06:00 am ET
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus placebo as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (RM-NPC), at the virtual American Society of Clinical Oncology (ASCO)
Apr 15, 2022 06:00 am ET
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted approval to BeiGene’s anti-PD-1 antib
Apr 11, 2022 06:00 am ET
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from the Phase 3 ALPINE trial showing BTK inhibitor BRUKINSA® (zanubrutinib) demonstrated superiority versus ibrutinib in overall response rate (ORR) as asse
Apr 08, 2022 07:00 am ET
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that clinical results, as well as biomarker data, from its immuno-oncology program in solid tumors will be presented at the American Academy for Cancer Research (AACR) Annual Meeting 2022. The AACR meeting will take place April 8-13, 2022, as a hybrid event in New Orleans and in a virtual format.
Apr 06, 2022 05:00 am ET
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that marketing authorization applications (MAA) for tislelizumab, submitted by Novartis, the license holder in E
Apr 03, 2022 06:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beigene, Ltd. - BGNE
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. ("Beigene" or the "Company") (NASDAQ: BGNE).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Mar 30, 2022 08:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beigene, Ltd. - BGNE
Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. (“Beigene” or the “Company”) (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 26, 2022 12:53 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beigene, Ltd. - BGNE
NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. ("Beigene" or the "Company") (NASDAQ: BGNE).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 21, 2022 08:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beigene, Ltd. - BGNE
Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. (“Beigene” or the “Company”) (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 16, 2022 08:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beigene, Ltd. - BGNE
NEW YORK, March 16, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beigene, Ltd. ("Beigene" or the "Company") (NASDAQ: BGNE).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Mar 15, 2022 08:00 am ET
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160, SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Medison Pharma Ltd. a global pharma company focused on providing access to highly innovative therapies to patients in international markets ("Medison"), today announced that the State of Israel Ministry of Health has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). BRUKINSA is reimbursed nationally f
Mar 11, 2022 07:00 am ET
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval to BeiGene’s ant
Mar 03, 2022 07:00 am ET
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
Mar 01, 2022 05:30 am ET
BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET.
Feb 25, 2022 07:00 am ET
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones.
Feb 22, 2022 07:00 am ET
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with marginal zone lymphoma (MZL).
Feb 22, 2022 07:00 am ET
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL is the most common form of adult leukemia. The Prescription Drug User Fee Act (PDUFA) target action da
Feb 17, 2022 05:00 am ET
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA (zanubrutinib) received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status.
Feb 08, 2022 06:00 am ET
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET.
Feb 01, 2022 07:00 am ET
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors. Dr. Dugan will join the scientific advisory committee and Dr. Riva will join the nominating and corporate governance, and scientific advisory committees of the board. In addition, Jing-Shyh (Sam) Su will be stepping down from BeiGene’s board of directors after serving
Jan 28, 2022 05:00 am ET
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for BeiGene’s BTK inhibitor BRUKINSA (zanubrutinib) as a treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and granted BRUKINSA breakthrough therapy designation (BTD).
Jan 24, 2022 05:00 am ET
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced positive findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. At the interim analysis, tislelizumab in combination with chemotherapy met the primary e
Jan 20, 2022 05:00 am ET
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for BeiGene’s BTK inhibitor BRUKINSA® (zanubrutinib) as a treatment for adult patients with Waldenström’s macroglobulinemia (WM).
Jan 06, 2022 07:30 am ET
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET.
Jan 06, 2022 03:30 am ET
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). A supplemental biologics license application for tislelizumab in this indication was previously accepted for review by the C
Dec 20, 2021 08:31 am ET
Thinking about trading options or stock in Novavax, Zoom Video Communications, Pfizer, Beigene, or Roku?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVAX, ZM, PFE, BGNE, and ROKU.
Dec 20, 2021 06:15 am ET
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan. In addition, the parties entered into an agreement granting BeiGene rights to market, promote and detail five approved Novartis oncology products, TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (ever
Dec 20, 2021 04:00 am ET
BeiGene Announces Launch of Bioisland Innovation Center
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced the official launch of the BeiGene Bioisland Innovation Center (BIC) in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world.
Dec 15, 2021 04:00 am ET
BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom’s MHRA for the Treatment of Adults with Waldenström’s Macroglobulinemia in Great Britain
BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for BRUKINSA® (zanubrutinib) in Great Britain, for the treatment of eligible adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of eligible patients unsuitable for chemo-immunotherapy.
Dec 14, 2021 11:00 pm ET
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it has completed its previously announced initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The shares offered in the STAR Offering were issued to and subscribed for by permitted investors in the People’s Republic of China (PRC) in Renminbi (RMB Shares). The RMB S
Dec 13, 2021 11:00 pm ET
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Nanjing Leads Biolabs, Inc. (Leads Biolabs), a privately-owned clinical stage biotechnology company in China and the U.S., today announced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway
Dec 12, 2021 09:30 am ET
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL), including the randomized Cohort 1 comparing BRUKINSA to bendamustine plus rituximab (B+R) and Cohort 3 (Arm D) of BRUKINSA in combination with venetoclax in patients with deletion of chromosome 17p (del[17p]) and/or pathogenic TP53 va
Dec 11, 2021 09:30 am ET
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today presented additional safety and efficacy results from an ongoing Phase 2 trial evaluating BRUKINSA® (zanubrutinib) in patients with previously treated B-cell malignancies who were intolerant to ibrutinib and/or acalabrutinib. These data were reported in a mini-oral presentation today at the 63rd American Society for Hematology (ASH) Annual Meeting.
Dec 10, 2021 03:00 am ET
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from the RATIONALE 309 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (RM-NPC) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021, taking place on December 8-11, 2021.
Dec 09, 2021 07:41 am ET
Direxion Launches mRNA ETF (MSGR)
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.
Dec 02, 2021 11:00 pm ET
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT® (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues. Siltuximab is a monoclonal antibody approved in the United States, European
Dec 02, 2021 11:00 pm ET
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT® (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues. Siltuximab is a monoclonal antibody approved in the United States, Europe
Dec 02, 2021 11:00 pm ET
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pam
BeiGene (NASDAQ:BGNE; HKEX:06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that three of its medicines have been added to the most recent National Reimbursement Drug List (NRDL) in China by the National Healthcare Security Administration (NHSA). BeiGene-discovered medicines in the updated NRDL include: anti-PD-1 antibody tislelizumab in three new indications, including in lung and liver cancers; BTK inhibitor BRUKINSA® (zanubrutinib) in one
Dec 02, 2021 03:00 am ET
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that clinical results and updates from its diverse immuno-oncology portfolio will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2021 being held December 8-11, 2021.
Nov 30, 2021 09:00 am ET
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the pricing of its previously announced initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The total number of shares being offered in the STAR Offering is 115,055,260 ordinary shares, par value $0.0001 per share, which represents 8.62% of BeiGene’s total outstanding ordinary shares
Nov 23, 2021 05:00 pm ET
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the European Commission (EC) approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. The approval is applicable to all 27 European Union (EU) member states, plus Iceland and Norway. BeiGene is working to make this new treatment option available to WM patients in the EU as quickly as possible.
Nov 23, 2021 08:15 am ET
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the commencement of an initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The total number of shares being offered in the STAR Offering is 115,055,260 ordinary shares, par value $0.0001 per share, which represents 8.62% of BeiGene’s total outstanding ordinary shares as of Oct
Nov 23, 2021 07:00 am ET
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative cancer medicines worldwide, announced today that it has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. to house a new state-of-the-art manufacturing campus and clinical R&D center. As a key part of BeiGene’s continued growth, the company is investing in U.S. manufacturing to further expand and diversify its global supply chain and build new manufacturing capabilities for its deep pipeline of biologic and drug candidates.
Nov 22, 2021 07:00 am ET
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists.
Nov 14, 2021 07:00 pm ET
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and NewBridge Pharmaceuticals, a specialty company in the Middle East and North Africa (MENA) regions established to bridge the access gap by partnering with global pharma and biotech companies, today announced that BRUKINSA® (zanubrutinib) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of adult patients with mantle cell lymphoma (MCL) who h
Nov 04, 2021 04:05 pm ET
BeiGene Reports Third Quarter 2021 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and nine months ended September 30, 2021.
Nov 04, 2021 09:00 am ET
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced clinical results and real world data from its hematology program to be presented at the 63rd American Society of Hematology (ASH)
Oct 20, 2021 07:00 am ET
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Nanolek, a biopharmaceutical company specializing in the production of import-substituting and innovative drugs in Russia, today announced that BRUKINSA® (zanubrutinib) has received approval from the Russia Ministry of Health for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BeiGene and Nanolek entered into an ex
Oct 10, 2021 05:00 pm ET
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On October 7, 2021, BRUKINSA received its initial approval in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior ther
Oct 07, 2021 04:06 pm ET
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy.1 Following registration of BRUKINSA with the Australia Therapeutic Goods Administration (TGA),
Oct 07, 2021 04:05 pm ET
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy.1 Following registration of BRUKINSA with the Therapeutic Goods Administration (TGA), these pati
Sep 20, 2021 07:00 am ET
BeiGene Announces Inclusion in FTSE Russell Indices
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, has announced its inclusion in several FTSE Russell indices, including: the FTSE Global Equity Index Large Cap; the FTSE All-World (LM); the FTSE All-Cap (LMS); and the FTSE Total-Cap (LMSµ). In addition,
Sep 17, 2021 09:31 am ET
Thinking about trading options or stock in Beigene, Upstart Holdings, American Airlines, Palantir Technologies, or GameStop?
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BGNE, UPST, AAL, PLTR, and GME.
Sep 17, 2021 08:00 am ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy.
Sep 15, 2021 07:00 am ET
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (
Sep 13, 2021 12:00 am ET
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy. The Prescription Drug User Fee Act (PDUFA) target action date is
Sep 12, 2021 06:05 pm ET
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and subgroup analyses from the Company’s robust lung cancer program will be presented at the European Society for Medical Oncology (ESMO) Congress 2021.
Sep 01, 2021 05:33 pm ET
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM)
Aug 22, 2021 07:00 pm ET
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for anti-PD-1 antibod
Aug 17, 2021 09:23 am ET
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma
BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA® (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed or refractory (R/R) neuroblastoma with or without residual disease. Dinutuximab beta is a targ